• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

WHO dispenses new advice on treating bird flu

MHSC

Senior Moderator
WHO dispenses new advice on treating bird flu


HELEN BRANSWELL
Canadian Press

Doctors caring for H5N1 patients should not treat them with corticosteroids, the World Health Organization said Thursday, noting that the drugs do not help and sometimes harm patients trying to battle the often-severe infection.


Corticosteroids should be used only on patients with persistent septic shock, a condition in which blood pressure drops to dangerous levels because of an infection in the bloodstream, the WHO advised in updated treatment guidelines published on its website.


The recommendation was one of several that emerged from a meeting last month in which physicians who have treated H5N1 patients gathered to share their experiences and observations.


The WHO-organized meeting, which took place in the Turkish town of Antalya, was an attempt to amalgamate data on as many human H5N1 cases as possible to answer questions about what works with these patients and what does not.
Related to this article

Internet Links
icon-link.gif


Latest Comments
icon-comment.gif


icon-digital-leaf-small-red.png

Pooling data on a large numbers of cases would allow patterns to come into focus that would not be apparent to doctors who treat only a patient or two.


Since H5N1 re-emerged in late 2003, nearly 300 people have been diagnosed with the infection, but those cases have spanned 12 countries, and in some countries such as Indonesia, infections have cropped up over a vast geographic area.


Those factors have made it difficult to amass knowledge about the best way to treat H5N1 patients ? a problem that the WHO is trying to rectify.


A fuller summary of the Antalya meeting will be submitted for publication to a peer-reviewed journal, the WHO's release said. In the meantime, however, it offered this advice to physicians faced with H5N1 cases:


? Early treatment with the antiviral drug oseltamivir (Tamiflu) seems to reduce the risk of death in H5N1 infections. But even late treatment with the drug ? which hinders the ability of the virus to replicate ? is useful because replication can last longer with the H5N1 avian virus than in infection with human flu viruses.


? Doctors can consider doubling the Tamiflu dose, giving it for longer or combining it with another flu drug, amantadine (in countries where H5N1 viruses are not resistant to this drug) if treating patients with progressive disease or pneumonia. A decision to alter oseltamivir treatment should be made on a case-by-case basis, the WHO said, asking doctors to collect data while they do it to help answer questions about whether these types of approaches are effective.


? Doctors should not treat patients with antibiotics as a means of trying to prevent secondary bacterial infections. If an H5N1 patient develops pneumonia, ideally testing should be done to determine if the cause is bacterial and therefore requires antibiotics.



http://www.theglobeandmail.com/serv...dflu0419/BNStory/specialScienceandHealth/home
 
Re: WHO dispenses new advice on treating bird flu

The interim report from the Turkey meeting...

Summary of the second WHO consultation on clinical aspects of human infection with avian influenza A(H5N1) virus
19-21 March, 2007, Antalya, Turkey

Since the last meeting in Hanoi, May 2005, eight new countries have reported human infections with avian influenza A(H5N1) viruses. Clinicians, epidemiologists, virologists and public health specialists from the countries with human cases, and experts in pulmonary medicine, critical care, and influenza attended the meeting to share their experiences.

Participants agreed that standardizing care and promptly sharing clinical and treatment information are critically important to understanding the disease in humans and to improving clinical management.

Observations and experiences, including unpublished data, were shared by participants during the consultation. Several conclusions regarding management of patients with H5N1 illness support and expand current WHO guidance (http://www.who.int/csr/disease/avian_influenza/guidelines/pharmamanagement/en/index.html):

? Experiences with early oseltamivir treatment suggest its usefulness in reducing H5N1-associated mortality. In addition, evidence of prolonged H5N1 virus replication indicates that treatment is warranted even with late presentation.

? As previously discussed, modified regimens of oseltamivir treatment, including two-fold higher dosage, longer duration and possibly combination therapy with amantadine (in countries where the H5N1 virus is susceptible to amantadine) may be considered on a case by case basis, especially in patients with pneumonia or progressive disease. Ideally this should be done in the context of prospective data collection.

? Corticosteroid therapy has failed so far to show effectiveness, and prolonged or high dose corticosteroids can result in serious adverse events in H5N1 patients, including opportunistic infection. Corticosteroids should not be used routinely, except for persistent septic shock with suspected adrenal insufficiency.

? Antibiotic prophylaxis should not be used. When pneumonia is present, antibiotic treatment is appropriate initially for community-acquired pneumonia according to published evidence-based guidelines. When available, the results of microbiologic studies should be used to guide antibiotic usage in patients with A(H5N1) infection.

? Therapy for H5N1-associated ARDS should be based upon published evidence-based guidelines for sepsis-associated ARDS, specifically including lung protective mechanical ventilation with low tidal volume.

The observations from the meeting will be published in greater detail, as an updated WHO guidance on H5N1 clinical management followed by a meeting summary in the form of peer-reviewed article in the scientific literature.

http://www.who.int/csr/disease/avian_influenza/guidelines/clinicalmeeting_19Apr_07.pdf
 
Back
Top